

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	754	(548/236).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:23
L2	1582	(514/374).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:24
L3	18	(("20040209920") or ("20040209931") or ("20040209932") or ("6221633") or ("6221897") or ("6245744") or ("6277831") or ("6342512") or ("6624185")).PN.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:24

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:04:15 ON 07 FEB 2006

=> fil reg
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:04:29 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4
DICTIONARY FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10789019.str




chain nodes :
6 7 8 11 12 14 15 16 17
ring nodes :
1 2 3 4 5
chain bonds :
7-11 7-12 8-12 8-14 11-17 14-15 14-16
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 4-5 7-11 7-12 8-12 8-14 11-17 14-15 14-16

G1:C,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS
12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED


=> d
L1 HAS NO ANSWERS
L1 STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\10789019.str



chain nodes :

6 7 8 11 12 14 15 16 17

ring nodes :

1 2 3 4 5

chain bonds :

7-11 7-12 8-12 8-14 11-17 14-15 14-16

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 7-11 7-12 8-12 8-14 11-17 14-15 14-16


G1:C,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS
12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L2 STRUCTURE UPLOADED

=> d
L2 HAS NO ANSWERS
L2 STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 08:05:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14001 TO ITERATE

14.3% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 272933 TO 287107
PROJECTED ANSWERS: 56 TO 504

L3 2 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 08:05:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 281879 TO ITERATE

100.0% PROCESSED 281879 ITERATIONS
SEARCH TIME: 00.00.04

238 ANSWERS

L4 238 SEA SSS FUL L1

=> s 14 and caplus/lc
49681526 CAPLUS/LC
L5 238 L4 AND CAPLUS/LC

=> s 12
SAMPLE SEARCH INITIATED 08:05:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 9828 TO ITERATE

20.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 190619 TO 202501
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L2

=> s 12 full
FULL SEARCH INITIATED 08:05:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 198499 TO ITERATE

100.0% PROCESSED 198499 ITERATIONS
0 ANSWERS
```

SEARCH TIME: 00.00.02

L7 0 SEA SSS FUL L2

=> fil caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
338.64	338.85

FILE 'CAPLUS' ENTERED AT 08:05:36 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 15
L8 19 L5

=> d ibib abs hitstr 1-19

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005126201 CAPLUS
 DOCUMENT NUMBER: 14422913
 TITLE: Preparation of arylcycloalkyl oxazole derivatives and their use as pharmaceuticals
 INVENTOR(S): Globlik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang
 PATENT ASSIGNEE(S): Germany
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 631,867.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005267177	A1	20051201	US 2005-97345	20050404
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
			DE 2001-10142734	A 20010831
PRIORITY APPLN. INFO.:			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801


GI



AB The title compds. I [ring A = (C3-C8)-cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, cyano, CF3, (C1-C6)-alkyl, O(C1-C6)-alkyl; R3 = H, (C1-C6)-alkyl; X, Y = (C1-C2)-alkyl where one C atom is replaced by O] and


L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of arylcycloalkyl-oxazole derivs. for pharmaceutical use)
 RN 501362-09-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-12-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-29-4 CAPLUS
 CN Benzoic acid, 2-[(4-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]-2-cyclopenten-1-yl)oxy]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-34-1 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 their physiol. acceptable salts and physiol. functional derivs. are disclosed. For example, reacting cyclopent-2-ene-1,4-diol with Me 2-(bromomethyl)-6-methylbenzoate followed by hydrolysis of the ester gave benzoic acid II. The compds. typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metab., of type II diabetes, and of syndrome X.


IT 710281-30-4P 710281-44-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)

RN 710281-30-4 CAPLUS

CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl-, methyl ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 710281-44-0 CAPLUS


CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-09-0P 501362-12-5P 501362-29-4P
 501362-34-1P 501362-35-2P 501362-38-5P
 501362-39-6P 501362-70-5P 501362-73-8P
 710281-33-7P 710281-34-8P 710281-35-9P
 710281-36-0P 710281-37-1P 710281-38-2P
 710281-39-3P 710281-40-6P 710281-42-8P
 710281-43-9P 710281-45-1P 710281-46-2P
 710281-48-4P 710281-49-5P 710281-50-8P
 710281-51-9P 870539-43-8P, 2-[(3-[(2-(4-Fluorophenyl)oxazol-4-yl)methoxy]cyclohexyl]oxy]-6-methylbenzoic acid 870539-53-0P 870539-58-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-35-2 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-38-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-39-6 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-70-5 CAPLUS


L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-73-8 CAPLUS
CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-33-7 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-34-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(3-trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 710281-35-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-36-0 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-37-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 710281-38-2 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-39-3 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-40-6 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-42-8 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 710281-43-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-cyanophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-45-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-46-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-48-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-49-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-50-8 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870539-58-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 870539-66-5P 870539-67-6P 870539-68-7P
 870539-69-8P 870539-70-1P 870539-71-2P
 870539-72-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses); (Preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)



RN 870539-66-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-67-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-51-9 CAPLUS
 CN Benzoic acid, 2-[(1S,3R)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-43-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)-6-methyl- (9CI) (CA INDEX NAME)




RN 870539-53-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-[2-(trifluoromethoxy)phenyl]-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-68-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-69-8 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-methoxy-3-methylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-70-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-71-2 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-72-3 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(5-ethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-08-9P 501362-11-4P 501362-14-7P
 501362-19-2P 501362-44-3P 501362-69-2P
 501362-72-7P 501362-75-0P 870539-42-7P, Methyl 2-[(3-[(2-(4-fluorophenyl)oxazol-4-yl)methoxy]cyclohexyl)oxy]-6-methylbenzoate 870539-51-0P 870539-55-2P 870539-56-3P 870539-62-1P 870539-65-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)
 RN 501362-08-9 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-11-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-19-2 CAPLUS
 CN Benzoic acid, 5-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-2-methyl-, ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-44-3 CAPLUS
 CN Benzoic acid, 2-[[[(3-[(2-(3-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-69-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-72-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-75-0 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-42-7 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 870539-51-8 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 870539-55-2 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-56-3 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 870539-62-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,4R)-4-[(2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-65-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-25-0 CAPLUS
 CN Benzoic acid, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl)-3-cyclohexen-1-yl]methoxy]methyl-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-26-1 CAPLUS
 CN Benzoic acid, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl)cyclohexyl]methoxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-28-3 CAPLUS
 CN Benzoic acid, 2-[(4-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)

IT 501362-06-7P 501362-20-5P 501362-21-6P
 501362-25-0P, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methylbenzoic acid
 501362-26-1P, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methylbenzoic acid
 501362-28-3P 501362-31-8P 501362-32-9P
 501362-33-0P 501362-36-3P 501362-37-4P
 501362-45-4P 501362-46-5P 501362-47-6P
 501362-48-7P 501362-49-8P 501362-50-1P
 501362-52-3P 501362-53-4P 501362-54-5P
 501362-55-6P 501362-58-9P 501362-59-0P
 501362-60-3P 501362-61-4P 501362-62-5P
 501362-67-0P 71028J-32-6P 870539-16-1P
 870539-48-3P 870539-49-4P 870539-52-9P
 870539-54-1P 870539-57-4P 870539-59-6P
 870539-63-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)


RN 501362-06-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-20-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-5-methyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-21-6 CAPLUS
 CN Benzoic acid, 2-[(1R,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-31-8 CAPLUS
 CN Benzoic acid, 2-[(1R,2R)-2-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclooctyl]oxy]methyl-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-32-9 CAPLUS
 CN Benzoic acid, 2-[(1R,2S)-2-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl]cyclohexyl]methoxy]methyl-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-33-0 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl)cyclohexyl]methoxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-36-3 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]methoxy-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS
 CN Benzoic acid, 2-[(trans-4-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)methoxy]-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-45-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-48-7 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-59-0 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-cyanophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS
 CN Benzoic acid, 2-[[3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-67-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-32-6 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-46-1 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 870539-54-1 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-57-4 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-59-6 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-63-2 CAPLUS




RN 870539-48-3 CAPLUS
 CN Benzoic acid, 2-[[[(1R,2R)-2-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 870539-49-4 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclooctyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 870539-52-9 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 870539-54-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1S,4R)-4-[(2-phenyl-4-oxazolyl)methoxy]cyclopenten-1-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1132917 CAPLUS
 DOCUMENT NUMBER: 143:405613
 TITLE: Preparation of α -substituted carboxylic acid as PPAR modulators
 INVENTOR(S): Bailey, Simon; Humphries, Paul Stewart; Skalitzky, Donald J.; Su, Wei Guo; Zehnder, Luke Raymond
 PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 150 pp.
 CODEN: USXKCD
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005234066	A1	20051020	US 2004-825923	20040415
US 2005187266	A1	20050825	US 2005-73274	20050304
PRIORITY APPLN. INFO.:			US 2003-463213P	P 20030415
			US 2004-825923	A2 20040415


OTHER SOURCE(S): MARPAT 143:405613
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [Ring Q = (C6-10)aryl or 4-10 membered heterocycl; R1 = H, halo, alkyl, alkoxy, CN, CF3, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR1R12)2n-, -(CR1R12)2n(CR1R12)n-, -(CR1R12)nNR10-, etc.; R5 = bond or -(CR1R12)2m-(CR1R12)s, wherein Z = -(CR1R12)2-, -O-, -NR10a-, or -SO-; R6 = CO2H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl or heterocycl; Ring A represents 3-7 membered cycloalkyl or heterocycl with provisions; R9 = alkyl, -(CR1R12)2taryl, -(CR1R12)2theterocycl wherein each R9 group may be substituted; R9a and R10 independently = H or alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO2; Z2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heteroaryl; m and s independently = 0-3; n = 0-4; P = 0-2; t = 0-5, as well as their pharmaceutically acceptable salts, are prepared. Thus, e.g., VI was prepared via coupling of Me 2-(3'-hydroxybiphenyl-3-yl)oxy-2-methylpropanoate (preparation given) with 2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethanol followed by hydrolysis. In scintillation proximity assays, I possessed Ki values between 0.3 nM to 30 μ M toward PPAR. Pharmaceutical compns. containing effective amts. of I, or their salts, are useful for treating PPAR, specifically PPAR α/γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

IT 784147-20-2P 784147-21-3P 784147-22-4P
 784147-33-78 784147-34-8P 784147-35-9P


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-34-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-35-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-36-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)methoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-37-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


784147-36-0P 784147-37-1P 784147-38-2P
 784147-39-3P 784147-40-6P 784147-41-7P
 784147-42-8P 784147-43-9P 784147-44-0P
 784147-45-1P 784147-46-2P 784147-47-3P
 784147-48-4P 784147-49-5P 784147-51-9P
 784147-52-0P 784147-53-1P 784147-54-2P
 784147-55-3P 784147-56-4P 784147-57-5P
 784147-58-6P 784147-59-7P 784147-60-0P
 784147-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate: prepn. of α -substituted carboxylic acid derivs. as PPAR modulators)


RN 784147-20-2 CAPLUS
 CN Cyclohexanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-21-3 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-22-4 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-33-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propenyl)phenyl)methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-39-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-40-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-41-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(2-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(4-aminocarbonyl)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-43-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-44-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-45-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-47-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-54-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-55-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2,5-diphenyl-4-oxazolyl]methoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-56-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-




RN 784147-48-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-49-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-51-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-53-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2,5-diphenyl-4-


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-59-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenoxy)- (9CI) (CA INDEX NAME)



RN 784147-60-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy)- (9CI) (CA INDEX NAME)



RN 784147-76-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy)phenoxy]- (9CI) (CA INDEX NAME)




IT 784148-97-4P 784148-88-5P 784148-94-3P
 784148-95-4P 784148-98-7P 784148-99-8P
 784149-00-4P 784149-02-6P 784149-03-7P
 784149-04-0P 784149-05-9P 784149-06-0P
 784149-07-1P 784149-09-3P 784149-12-8P
 784149-15-1P 784149-16-2P 784149-83-3P
 784149-84-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of α -substituted carboxylic acid derivs.)


as

PPAR modulators)


RN 784148-87-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 1-(hydroxy[4-(2-(5-methyl-2-phenyl-4-




RN 784148-88-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784148-94-3 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-95-4 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[(4-[(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy)phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-98-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(3-(dimethylamino)phenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-04-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-05-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-07-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784148-99-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(2-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-00-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(4-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(3-fluoro-3-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-09-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-12-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy)phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-83-3 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-84-4 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005-904348 CAPLUS
DOCUMENT NUMBER: 143-248077
TITLE: Preparation of alpha substituted carboxylic acid as PPAR modulators
INVENTOR(S): Su, Wei Guo
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 128 pp., Cont.-in-part of U.S. Ser. No. 825,923.
CODEN: USXK00
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187266	A1	20050825	US 2005-73274	20050304
US 2005234066	A1	20051020	US 2004-825923	20040415
PRIORITY APPLN. INFO.:			US 2003-463213P	P 20030415
			US 2004-825923	A2 20040415

OTHER SOURCE(S): MARPAT 143:248077
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ring Q = (C6-10)aryl or 4-10 membered heterocycl; R1 = H, halo, alkyl, alkoxy, CN, CF3, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR1R2)2n-, -(CR1R2)2nS(CR1R2)2n-, -(CR1R2)2nR10-, etc.; R5 = bond or -(CR1R2)2m-, -(CR1R2)2s, wherein Z = -(CR1R2)2-, -O-, -NR10a-, or -SO-; R6 = CO2H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl or heterocycl; Ring A represents 3-7 membered cycloalkyl or heterocycl with provisions; R9 = alkyl, -(CR1R2)2aryl, -(CR1R2)2heterocycl wherein each R9 group may be substituted; R9a and R10 independently = H or alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO2; Y2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heteroaryl; m and s independently = 0-3; n = 0-4; p = 0-2; t = 0-5], as well as their pharmaceutically acceptable salts, are prepared as PPAR modulators. Thus, e.g., VI (disclosed compound I) was prepared in 47% yield via hydrolysis of its Me ester. In scintillation proximity assays, I possessed Ki values between 0.3 nM to 30 μ M toward PPAR. Pharmaceutical compns. containing effective amts. of I, or their salts, are useful for treating PPAR, specifically PPAR α/γ related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.


IT 784147-20-2P 784147-21-3P 784147-22-4P
784147-33-7P 784147-34-8P 784147-35-9P
784147-36-0P 784147-37-1P 784147-38-2P
784147-39-3P 784147-40-6P 784147-41-1P

RN 784147-42-0P 784147-43-0P 784147-44-0P
784147-45-1P 784147-46-2P 784147-47-3P
784147-48-4P 784147-49-5P 784147-51-9P
784147-52-0P 784147-53-1P 784147-54-2P
784147-55-3P 784147-56-4P 784147-57-5P
784147-58-6P 784147-59-7P 784147-60-0P
784147-76-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO1 (Biological study); PREP (Preparation); USES (Uses)

Uses (drug candidate; prepns. of α -substituted carboxylic acid derivs. as PPAR modulators)


RN 784147-20-2 CAPLUS
CN Cyclohexanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-21-3 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-22-4 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-33-7 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-34-8 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-35-9 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-36-0 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-37-1 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-39-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)





RN 784147-40-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-41-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[4-(aminocarbonyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-48-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[5-methyl-2-(3-trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-49-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-51-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[5-methyl-2-(4-trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-53-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-diphenyl-4-


RN 784147-43-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-44-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-45-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-47-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-54-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(2,5-diphenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-55-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2,5-diphenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-56-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-phenyl-4-




RN 784147-59-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(3-methyl-2-phenyl-4-oxazolyl)propoxy]phenoxy- (9CI) (CA INDEX NAME)



RN 784147-60-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy- (9CI) (CA INDEX NAME)




RN 784147-76-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(1,1'-biphenyl)-4-yl-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




IT 784148-87-4P 784148-88-5P 784148-94-3P
 784148-95-4P 784148-98-7P 784148-99-6P
 784149-00-4P 784149-02-6P 784149-03-7P
 784149-04-8P 784149-05-9P 784149-06-0P
 784149-07-1P 784149-09-3P 784149-12-6P
 784149-15-1P 784149-16-2P 784149-03-3P
 784149-84-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate) preparation of α -substituted carboxylic acid derivs.
 as PPAR modulators)


RN 784149-87-4 CAPLUS
 CN Cyclohexanecarboxylic acid, 1-[hydroxy]4-(2-(5-methyl-2-phenyl-4-




RN 784149-99-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(2-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-00-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(4-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784148-88-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[hydroxy]4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784148-94-3 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784148-95-4 CAPLUS
 CN Cyclopentanecarboxylic acid, 1-[4-(3-(dimethylamino)phenyl)-5-methyl-4-oxazolyl]ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-98-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(3-(dimethylamino)phenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-04-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-05-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-07-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[4-(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy]phenylmethyl- (9CI) (CA INDEX NAME)




RN 784149-09-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-12-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-83-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-84-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2005:508852 CAPLUS

DOCUMENT NUMBER: 143:115351

TITLE: Preparation of 2-(phenoxyethyl)benzoic acids
Fiedler, Wolfgang; Neises, Bernd; Hachtel, Jochen

INVENTOR(S): Aventis Pharma Deutschland G.m.b.H., Germany

PATENT ASSIGNEE(S): PCT Int. Appl., 36 pp.

SOURCE: CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061427	A2	20050707	WO 2004-EP14602	20041222
WO 2005061427	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10360525	B3	20050818	DE 2003-10360525	20031222
US 2005171205	A1	20050804	US 2004-18038	20041221
PRIORITY APPLN. INFO.:			DE 2003-10360525	A 20031222
			US 2004-587798P	P 20040714

OTHER SOURCE(S): CASREACT 143:115351
GI

I



II


AB Title compds. I [R = alkyl, heterocycle, aryl, etc.; R1 = X1m; X1 = halo,

alkyl, alkoxy, etc.; m = 0-4; R2 = (X2m); X2 = halo, alkoxy, etc.] were prep'd via the esterification of phthalides with resorcinols, followed by O-alkylation. For example, benzylbromide O-alkylation of resorcinol II (R = H) afforded 2-(phenoxyethyl)benzoic acid II (R = PhCH2) in 47% yield. Compds. I are suitable as peroxisome proliferator activated receptor (PPAR) modulators (no data provided).


IT 303218-47-5P 303219-55-8P

RL: SPA (Synthetic preparation); PREP (Preparation)
(preparation of 2-(phenoxyethyl)benzoic acids)

RN 303218-47-5 CAPLUS

CN Benzoic acid,
2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

RN 303219-55-8 CAPLUS

CN Benzoic acid,
2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:260039 CAPLUS

DOCUMENT NUMBER: 142:336130

TITLE: Preparation of substituted benzoic acids for treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPARs)
INVENTOR(S): Damon, Robert Edison; Vedananda, Thalaththani Raleilage
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl. 85 pp.
CODEN: PIKXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026134	A1	20050324	WO 2004-EPI0393	20040916
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:		US 2003-5039508	P 20030917	

OTHER SOURCE(S): MARPAT 142:336130
GI



AB The title compds. I [R1 = H, alkyl, (hetero)aryl, aralkyl, cycloalkyl; R2,

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
R3 = H, halo, OH, CN, etc.; or R2 and R3 combined together with the carbon

atoms they are attached to form (un)substituted fused 5-6 membered (heteroaryl; R4, R5 = H, halo, alkyl, alkoxy, (hetero)alkyl; R4C and R5C may be replaced by nitrogen atom; X = Z(CH2)pGW (wherein Z = a bond, O, S, SO, CO, etc.; p = 1-8; Q = a bond, CO, O(CH2)1-8, etc.; W = cycloalkyl, aryl, heterocycl, etc.); AB = NHSO2, Y(R8)2 (Y = O, S; R8 = H, alkyl)] which bind to Peroxisome Proliferator-Activated Receptors (PPARs), were prep. E.g., a multi-step synthesis of II, starting from sodium 4-hydroxybenzenesulfonate dihydrate, was given. The compd. II showed an EC50 of about 8 nM in the PPAR α receptor binding assay, an EC50 of about 5 nM in the PPAR γ receptor binding assay, and an EC50 of about 3500 nM in the PPAR δ receptor binding assay. Furthermore, the compd. II significantly lowers serum glucose and insulin levels at a daily dose of about 30 mg/kg p.o. in the ob/ob mice. The compds. I are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertension, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compds. of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes,

and Syndrome X. The pharmaceutical compns. comprising the compd. I and other therapeutic agents are disclosed.

IT 848569-53-9 848569-54-0 848569-55-1P

848569-56-2P 848569-57-3P 848569-58-4P

848569-59-5P 848569-60-0P 848569-61-9P

848569-62-0P 848569-63-1P 848569-64-2P

848569-65-3P 848569-66-4P 848569-67-5P

848569-68-6P 848569-69-7P 848569-70-0P

848569-71-1P 848569-72-2P 848569-73-3P

848569-74-4P 848569-75-5P 848569-76-6P

848569-77-7P 848569-78-8P 848569-79-9P

848569-80-2P 848569-91-5P 848569-92-6P

848569-93-7P 848569-94-8P

RL: PRC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted benzoic acids for treating conditions mediated

by Peroxisome Proliferator-Activated Receptors (PPARs))

RN 848569-53-9 CAPLUS


CN Benzoic acid, 2-methyl-6-[(4-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl)methoxy-, methyl ester (9CI) (CA INDEX NAME)

INDEX


NAME)

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 848569-54-0 CAPLUS
CN Benzoic acid, 4-methoxy-2-[(4-[(2-(5-methyl-2-phenyl-4-


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 848569-54-0 CAPLUS
CN Benzoic acid, 2-[(4-[(2-(5-methyl-2-phenyl-4-


oxazolyl)ethoxy]phenyl)methoxy]ethoxy-

(9CI) (CA INDEX NAME)



RN 848569-55-1 CAPLUS


CN Benzoic acid, 2-methyl-6-[(4-[(2-(5-methyl-2-phenyl-4-



RN 848569-55-1 CAPLUS


CN Benzoic acid, 4-methyl-2-[(4-[(2-(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-56-2 CAPLUS


CN Benzoic acid, 4-chloro-2-[(4-[(2-(5-methyl-2-phenyl-4-



RN 848569-60-8 CAPLUS


CN Benzoic acid, 4-chloro-2-[(4-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-57-3 CAPLUS


CN 2-Naphthalenecarboxylic acid, 3-[(4-[(2-(5-methyl-2-phenyl-4-




RN 848569-61-9 CAPLUS

CN Benzoic acid, 4-chloro-2-[(4-[(5-methyl-2-phenyl-4-


oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-62-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-4-propoxy- (9CI) (CA INDEX NAME)




RN 848569-63-1 CAPLUS
 CN Benzoic acid, 2-methyl-4-(1-methylethoxy)-6-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-64-2 CAPLUS
 CN Benzoic acid, 2,4-dimethoxy-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-65-3 CAPLUS
 CN Benzoic acid, 2,4-dimethoxy-6-[(4-[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-70-0 CAPLUS
 CN Benzoic acid, 2-methyl-4-(1-methylethoxy)-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-71-1 CAPLUS
 CN Benzoic acid, 2-fluoro-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-72-2 CAPLUS
 CN Benzoic acid, 2-methoxy-6-[(4-[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-73-3 CAPLUS
 CN Benzoic acid, 2-methoxy-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-66-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(4-[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]-4-propoxy- (9CI) (CA INDEX NAME)




RN 848569-67-5 CAPLUS
 CN Benzoic acid, 2-[{4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 848569-68-6 CAPLUS
 CN Benzoic acid, 2-[{4-[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 848569-69-7 CAPLUS
 CN Benzoic acid, 2-fluoro-6-[(4-[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-74-4 CAPLUS
 CN Benzoic acid, 4-chloro-2-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-75-5 CAPLUS
 CN Benzoic acid, 2-[(4-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methoxy]-6-methyl-4-(1-methylpropoxy)- (9CI) (CA INDEX NAME)




RN 848569-76-6 CAPLUS
 CN Benzoic acid, 4-fluoro-2-[(4-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methoxy]-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 848569-77-7 CAPLUS


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 4-fluoro-2-[(4-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy)phenyl]-6-propoxy- (9CI) (CA INDEX NAME)




RN 848569-78-8 CAPLUS
 CN Benzoic acid, 2-[(4-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy)phenyl]-6-methyl-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 848569-79-9 CAPLUS
 CN Benzoic acid, 2-methyl-4-(1-methylethoxy)-6-[(4-[2-(5-methyl-2-(4-trifluoromethyl)phenyl)-4-oxazolyl]ethoxy)phenyl]methoxy- (9CI) (CA INDEX NAME)




RN 848569-80-2 CAPLUS
 CN Benzoic acid, 2-[(4-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]phenyl)methoxy]-6-methyl-4-[(tetrahydro-3-furanyl)oxy]methyl- (9CI) (CA INDEX NAME)




PAGE 1-A

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 848569-89-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted benzoic acids for treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPARs))

RN 848569-89-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-2-propenyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PAGE 1-B




RN 848569-91-5 CAPLUS
 CN 1-Naphthalene carboxylic acid, 2-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-92-6 CAPLUS
 CN Benzoic acid, 4-chloro-2-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-93-7 CAPLUS
 CN Benzoic acid, 4-chloro-2-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-94-8 CAPLUS
 CN Benzoic acid, 2-[(4-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methoxy]-6-methyl-4-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005120864 CAPLUS
 DOCUMENT NUMBER: 142:219048
 TITLE: Preparation of diphenyl ether derivatives as PPAR_α agonists
 INVENTOR(S): Kusuda, Shinya; Nakayama, Yoshiyuki; Ima, Masaki; Tajima, Hisao; Kato, Sachiko
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 134 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012221	A1	20050210	WO 2004-JP1424	20040803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KE, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2003-286199	A 20030804

OTHER SOURCE(S): MARPAT 142:219048
 GI



AB The title compds. I (wherein rings A, B, and D = independently (un)substituted (hetero)cycles; W = a spacer; X = a spacer; Y = a bond or a spacer; Z = an acid group), or salts, solvates, or prodrugs thereof are

L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 prep'd. as peroxisome proliferator-activated receptors (PPAR) agonists. For example, the compd. II was prep'd. in a multi-step synthesis. II increased HDL level and lowered LDL level in rat. I are useful as a preventive and/or therapeutic agent for diseases caused by sugar/lipid abnormal metab. (diabetes, hyperlipemia, arteriosclerosis, cardiovascular diseases, obesity, metabolic syndrome, etc.), hypertension, circulatory diseases, inflammatory skin diseases, etc. (no data). Formulations

contg. I as an active ingredient were also described.

IT 840542-59-8P 840542-63-4P 840542-66-7P


840542-94-1P 840543-25-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of di-Ph ether derivs. as PPAR δ agonists)


RN 840542-59-8 CAPLUS

CN Benzoic acid, 2-[3-{2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 840542-63-4 CAPLUS

CN Benzoic acid, 3-[3-{(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-66-7 CAPLUS

CN Benzoic acid, 3-[3-{[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-94-1 CAPLUS

CN Benzoic acid, 3-[2-{2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:902360 CAPLUS

DOCUMENT NUMBER: 141:379637

TITLE: Preparation of α -alpha substituted carboxylic acid as ppar modulators

INVENTOR(S): Bailey, Simon; Humphries, Paul Stuart; Skalitzky, Donald James; Su, Wei-Guo; Zehnder, Luke Raymond

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 177 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092145	A1	20041028	WO 2004-IB1159	20040401
WO 2004092145	C1	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW, RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2521915	AA	20041028	CA 2004-2521915	20040401
EP 1615899	A1	20060118	EP 2004-725121	20040401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
NL 1025946	A1	20041018	NL 2004-1025946	20040414
NL 1025946	C2	20050201	US 2003-463213P	P 20030415
PRIORITY APPLN. INFO.:				
			WO 2004-IB1159	W 20040401

OTHER SOURCE(S): MARPAT 141:379637
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I (Ring Q = [C6-10]aryl or 4-10 membered heterocyclyl; R1 = H, halo, alkyl, alkoxy, CN, CF₃, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR₁R₁₂)_n, -(CR₁R₁₂)_nS(CR₁R₁₂)_n, -(CR₁R₁₂)_nR10, etc.; R5 = bond or -(CR₁R₁₂)_m-(CR₁R₁₂)_n, wherein Z = -(CR₁R₁₂)_n-O-, -NR10-, or -SO-; R6 = CO₂H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl or heterocyclyl; Ring A represents 3-7 membered cycloalkyl or heterocyclyl with provisions; R9 = alkyl, -(CR₁R₁₂)_ntaryl, -(CR₁R₁₂)_nheterocyclyl wherein each R9 group may be substituted; R9a and R10 independently = H or

L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 840543-25-1 CAPLUS

CN Benzoic acid, 3-[2-[(5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

THIS

15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO₂; Y2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heterocarly; m and n independently = 0-3; n = 0-4; p = 0-2; t = 0-5, as well as their pharmaceutically acceptable salts, are prep'd. and disclosed as PPAR modulators. Thus, e.g., VI was prep'd. via coupling of Me 2-[3'-hydroxybiphenyl-3-yl]oxy]-2-methylpropanoate (prepn. given) with 2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethanol followed by hydrolysis. In scintillation proximity assays,

I possessed Ki values between 0.3 nM to 30 μ M toward PPAR. Pharmaceutical compns. contg. effective amt.s. of I, or their salts, are useful for treating PPAR, specifically PPAR α /y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

IT 784147-20-2P 784147-21-3P 784147-22-4P

784147-33-7P 784147-34-8P 784147-35-9P

784147-36-0P 784147-37-1P 784147-38-2P

784147-39-3P 784147-40-6P 784147-41-7P

784147-42-4P 784147-43-9P 784147-44-0P

784147-45-1P 784147-46-2P 784147-47-3P

784147-48-4P 784147-49-5P 784147-51-9P

784147-52-0P 784147-53-1P 784147-54-2P

784147-55-3P 784147-56-4P 784147-57-5P

784147-58-6P 784147-59-7P 784147-60-0P


784147-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of α -substituted carboxylic acid derivs. as ppar modulators)


RN 784147-20-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-21-3 CAPLUS

CN Cyclopentanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-22-4 CAPLUS


CN Cyclopentanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-33-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenylphenyl]methyl)- (9CI) (CA INDEX NAME)




RN 784147-34-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 784147-35-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-36-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-((5-methyl-2-phenyl-4-oxazolyl)methoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-37-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(4-(aminocarbonyl)phenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-43-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-44-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-45-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-39-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-40-6 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(2-(3-(dimethylamino)phenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-41-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(2-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS




RN 784147-47-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-48-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-49-5 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-51-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-(2-(5-methyl-2-(4-chlorophenyl)-4-oxazolyl)ethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 784147-53-1 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(2,5-diphenyl-4-oxazolyl)methoxy]phenyl]methyl- (9CI) (CA INDEX NAME)




RN 784147-54-2 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(3-(2,5-diphenyl-4-oxazolyl)propoxy)phenyl]methyl- (9CI) (CA INDEX NAME)



RN 784147-55-3 CAPLUS
CN Cyclobutanecarboxylic acid, 1-(4-[(2,5-diphenyl-4-oxazolyl)methoxy]phenoxy)- (9CI) (CA INDEX NAME)



RN 784147-56-4 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(3-(2,5-diphenyl-4-oxazolyl)propoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
784149-00-4P 784149-02-6P 784149-03-7P
784149-04-8P 784149-05-9P 784149-06-0P
784149-07-1P 784149-09-3P 784149-12-6P
784149-15-1P 784149-16-2P 784149-83-3P
784149-84-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of α -substituted carboxylic acid derivs. as ppac modulators)


RN 784149-87-4 CAPLUS
CN Cyclohexanecarboxylic acid, 1-[hydroxy(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784149-88-5 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[hydroxy(4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-94-3 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[(4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784149-95-4 CAPLUS
CN Cyclopentanecarboxylic acid, 1-[(4-(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy)phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-59-7 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-60-0 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-76-8 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




IT 784149-97-4P 784149-98-5P 784149-94-3P
784149-95-4P 784149-98-7P 784149-99-8P




RN 784149-98-7 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(2-[2-(3-(dimethylaminophenoxy)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-99-8 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(2-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-00-4 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(4-cyanophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS
CN Cyclobutanecarboxylic acid, 1-[(4-[(2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-04-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-05-9 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-07-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-09-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-12-8 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[2-(5-methyl-2-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-83-3 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-84-4 CAPLUS
 CN Cyclobutanecarboxylic acid, 1-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

ACCESSION NUMBER: 2004:740308 CAPLUS
 DOCUMENT NUMBER: 141:260737
 TITLE: Preparation of 4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid derivatives as PPAR modulators for treating diabetes and atherosclerosis
 INVENTOR(S): Stepper, Christian; Keil, Stefanie; Glombik, Heiner; Falk, Eugen; Goerlitzer, Jochen; Gretzke, Dirk; Schaefer, Hans-Ludwig; Wendler, Wolfgang
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: PCT Int. Appl., 163 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076428	A1	20040910	WO 2004-EP1586	20040219
W 2004076428	A1	20040910	W 2004-EP1586	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	A1	20041223	DE 2003-10308355	20030227
CA 2517386	AA	20040910	CA 2004-2517386	20040219
EP 1599455	A1	20051130	EP 2004-712503	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	A1	20041021	US 200410920	20040227
US 2004209920	A1	20041021	US 2004-789017	20040227
US 2005010637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
NO 2005004398	A	20051102	NO 2005-4398	20050922
PRIORITY APPLN. INFO.:			DE 2003-10308355	A 20030227
			US 2003-487510P	P 20030715
			WO 2004-EP1586	W 20040219

OTHER SOURCE(S): MARPAT 141:260737
 GI



II

AB Title compds. I [A = cycloalkanediyl, cycloalkenediyl, etc.; R1-2 = H, F, Cl, etc.; R3 = H, alkyl, cycloalkyl, etc.; X = CH, N, etc.; p = 0-1; X = alkanediyl, etc.; Y1 = O; Y2 = alkyl, SO1-2; n = 0-2; R4-5 = H, F, alkyl; R6 = H, alkyl, etc.; R7 = H, alk(en)yl, Ph, etc.; R8 = H, alkyl] are prepared. For instance, 2-Ethyl-4-((1R,3S)-3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid (II) is prepared in

7 steps from 1,3-cyclohexanediol and 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole (preparation given). II has EC50 = 41 nM for the PPAR_α receptor. I are useful for the treatment of, e.g., disorders in the metabolism of fatty acids.

IT 756495-56-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid derivs. as PPAR modulators for treating diabetes and atherosclerosis)

RN 756495-56-4 CAPLUS

CN Cyclopropanecarboxylic acid,

1-[(1R,3S)-3-((5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 756496-45-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid)

L8 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:740307 CAPLUS
DOCUMENT NUMBER: 141:260736
TITLE: Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivatives
and related compounds used as PPAR modulators for
treating type 2 diabetes and arteriosclerosis
INVENTOR(S): Stapper, Christian; Gretzke, Dirk; Glombik, Heiner;
Falk, Eugen; Goerlitzer, Jochen; Keil, Stefanie;
Schaefer, Hans-Ludwig; Wendler, Wolfgang
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 189 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076427	A1	20040910	WO 2004-EP1579	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308355	A1	20041223	DE 2003-10308355	20030227
CA 2517381	AA	20040910	CA 2004-2517381	20040219
EP 1599452	A1	20051130	EP 2004-712490	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004209920	A1	20041021	US 2004-789017	20040227
US 2005101637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
NO 2005004408	A	20051123	NO 2005-4408	20050922
PRIORITY APPLN. INFO.:			DE 2003-10308355	A 20030227
			US 2003-487510P	P 20030715
			WO 2004-EP1579	W 20040219

OTHER SOURCE(S): MARPAT 141:260736
GI.

L8 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(Continued)
derivs. as PPAR modulators for treating diabetes and atherosclerosis
RN 756496-45-4 CAPLUS
CN Cyclopropanecarboxylic acid,
1-[(1R,3S)-3-((5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L8 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [X = alkanediyl, oxalkanediyl, cycloalkenediyl, oxacycloalkanediyl, oxacycloalkenediyl; Y1 = (un)substituted CH2, CH2CH2, O, S(O), SO2, (un)substituted NH; R = (un)substituted or annulated Ph, pyridinyl, furyl, thiienyl, pyrrolyl; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, Ph, aralkyl, heteroaryl, heteroarylalkyl, fluoroalkyl; R2, R3 = H, alkyl, F, (un)substituted NH; R4 = H, alkyl, F; R5 = H, F, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, Ph, substituted alkyl; CR4R5 = cycloalkyl; R6 = H, alkyl] were prepared for use as PPAR modulators for treating disorders of the fatty acid metabolism and disorders of glucose utilization in addition to

disorders, in which insulin resistance plays a part. Thus, the title compound II was prepared in a multi-stage synthesis and had EC50 for activation of the PPAR receptor of 0.07 nM.

IT 754986-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic


acid derivs. and related compds. as PPAR agonists)

RN 754986-25-9 CAPLUS

CN Cyclopentane carboxylic acid,


1-[(1R,3S)-3-((5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 754986-24-8
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivs. and related compds. as PPAR agonists)
 RN 754986-24-8 CAPLUS
 CN Cyclopentanecarboxylic acid,
 1-[(1R,3S)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]methoxy-, 1,1-dimethylethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 754987-29-6
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivs. and related compds. as PPAR agonists)
 RN 754987-29-6 CAPLUS
 CN Cyclopentanecarboxylic acid,
 1-[(1R,3R)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004-740279 CAPLUS
 DOCUMENT NUMBER: 141:260285
 TITLE: Method for producing the enantiomeric forms of cis-1,3-cyclohexanediol derivatives using an enzymic resolution
 INVENTOR(S): Holla, Wolfgang; Keil, Stefanie
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: PCT Int. Appl., 91 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076390	A1	20040910	WO 2004-EP1580	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, D2, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, C2, EE, HU, SK				
DE 10308350	A1	20040916	DE 2003-10308350	20030227
CA 2516623	AA	20040910	CA 2004-2516623	20040219
EP 1599433	A1	20051130	EP 2004-712518	20040219
US 2004209931	A1	20041021	US 2004-789053	20040227
NO 2005004456	A	20050926	NO 2005-4456	20050926
PRIORITY APPLN. INFO.:			DE 2003-10308350	A 20030227
			US 2003-487416P	P 20030715
			WO 2004-EP1580	W 20040219

OTHER SOURCE(S): MARPAT 141:260285
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a method for producing chiral, non-racemic, disubstituted cis-1,3-cyclohexanediols I (R1 = R'; A = Ph, 5- to 10-membered heteroarom. (containing N, O, S), C8-14-aromatic, C3-8-cycloalkyl; R3 = H, F, Cl, Br, OH, NO2, CF3, OCF3, Cl-6-alkyl, C8-8-cycloalkyl, Ph; R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, OCF2CF3, OCF2CHF2, SCF3, OPh, Cl-6-alkyl, O-(Cl-6-alkyl), O-(Cl-3-alkyl); n = 1 - 3; R2 = Cl-8-alkyl, optionally, one or more CH2 may be replaced with an O, CO, S, SO2 and substituted with 1 - 3 substituents (F, Cl, Br, CF3, CN, NO2, NHAc, NHBOC, NHCOOMe3, OH, OCF3, O-(Cl-6-alkyl), CO2H, CO2CH2Ph, CO2-(Cl-6-alkyl), tetrazole, indole, (un)substituted thiazolidine-2,4-dione, C6-10-aryl), or, protecting group (PG) (e.g., CH2OCH2Ph, CH2Ph, CH2C6H4OMe-p, SiMe2CHMe3) using an enzymic resolution of racemates. The

L8 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 prep. of chiral cis-I is characterized by: (a) alkylation of (1R)-cis-1,3-cyclohexanediol with R2X1 (X1 = Cl, Br, I, OSO2Me (OMs), OSO2C6H4Me-p (OMs), OSO2CF3 (OTf)) in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resoln. of (1R)-cis-I (R1 = H) with an acyl donor, R6Cl or (R6)2O (R6 = C(=O)-(C1-16-alkyl), C(=O)-(C2-16-alkenyl), C(=O)-(C3-16-alkynyl), C(=O)-(C3-16-cycloalkyl), optionally one or more CH2 may be replaced with O substituted with 1 - 3 substituents (F, Cl, Br, CF3, CN, NO2, OH, OMe, OEt, Ph, CO2-(C1-4-alkyl), CO2-(C2-4-alkenyl))), in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6); (d) alkylation of chiral cis-I (R1 = H) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent. Alternatively chiral cis-I is prep'd. by: (a) alkylation of (1R)-cis-1,3-cyclohexanediol with PG-X1 (X1 = Cl, Br, I, OMs, OTs, OTf) in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resoln. of (1R)-cis-I (R1 = H, R2 = PG) with an acyl donor, R6Cl or (R6)2O, in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6, R2 = PG); (d) alkylation of chiral cis-I (R1 = H, R2 = PG) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent (e) deprotecting chiral cis-I (R2 = PG); (f) alkylation of chiral cis-I (R2 = H) with R2X1 in the presence of a base and a suitable solvent. Thus, cyclohexanediol deriv. II was prep'd. from (1R)-cis-1,3-cyclohexanediol via alkylation with Me 2-(bromomethyl)-6-methylbenzoate in NMP contg. KOMe3, enzymic resoln. with vinyl acetate in CH2Cl2 contg. Novozym 435, alkylation of the resulting chiral (benzyloxy)cyclohexanol III with (iodomethyl)oxazole IV, and sapon. with NaOH in EtOH.


IT 501362-77-2 710281-33-7 710281-37-1P

710281-48-4P 755030-33-2P 755030-34-3P

RL: BPN (Biological preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep. of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution)


RN 501362-77-2 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-33-7 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-37-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-((1R,3S)-3-((5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-48-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-((1R,3S)-3-((5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755030-33-2 CAPLUS
 CN Benzoic acid, 2-((1S,3R)-3-((2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 755030-27-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-((1R,3S)-3-((5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS FORMAT



RN 755030-34-3 CAPLUS
 CN Benzoic acid, 2-((1S,3R)-3-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 755030-19-4P 755030-23-OP 755030-27-4P

RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); (preparation and saponification of; prepn of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution)

RN 755030-19-4 CAPLUS
 CN Benzoic acid, 2-((1R,3S)-3-((2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755030-23-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-((1R,3S)-3-((5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl-, methyl ester (9CI) (CA INDEX NAME)

TITLE: Production method for 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups and use thereof as medicaments

INVENTOR(S): Goerlitzer, Jochen; Glombik, Heiner; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 108 pp.

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075891	A1	20040910	WO 2004-EP1582	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NA, NJ, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308351	A1	20041125	DE 2003-10308351	20030227
CA 2517307	AA	20040910	CA 2004-2517307	20040219
EP 1599203	A1	20051130	EP 2004-712489	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004209932	A1	20041021	US 2004-789281	20040227
PRIORITY APPLN. INFO.:			DE 2003-10308351	A 20030227
			US 2003-487566P	P 20030715
			WO 2004-EP1582	W 20040219

OTHER SOURCE(S): MARPAT 141:260735
 GI



I



II

AB The invention relates to 1,3-disubstituted cycloalkyl derivs. containing acidic, mainly heterocyclic groups, in addition to their physiol. compatible salts and physiol. functional derivs. The invention relates to compds. I (A = C3-8-cycloalkanediyl, C3-8-cycloalkenediyl (optionally containing an O instead of one C); E (CH2); R1, R2 = H, F, Cl, SF5, S-(Cl-6-alkyl), CF3, OCF3, Cl-6-alkyl, O-(Cl-6-alkyl), OCF3, OPh, OCF2CHF2, OCF2CF3, (Cl-6-alkyl)-(Cl-6-alkoxy), O-(Cl-6-alkyl)-(Cl-6-alkoxy), OCH2Ph; R3 = H, CF3, Cl-6-alkyl, C3-8-cycloalkyl, Ph; X = Cl-6-alkanediyl (optionally containing an O instead of C); Y = S, O, bond; m = 1-3; n = 0, 1; Z = O, S, C:O, C:(O)NH; R = H, OH, CH2CONHOH, CH2CONH(C1-6-alkyl), CH2CONH(Cl-6-alkoxy), NR4R5, 5- to 12-membered mono- or bicyclic, (un)saturated ring containing 1 or more N, O, S; R4 = H, Cl-6-alkyl (optionally substituted with F, Cl, Br, CN, SH, CO2H, Cl-4-alkyl, Cl-6-alkoxy, SO2-(Cl-4-alkyl), NO2, CF3, OCF3, (Cl-6-alkyl)-(Cl-6-alkoxy), (Cl-6-alkoxy)-(Cl-6-alkoxy), (Cl-6-alkoxy)-(Cl-6-alkoxy)C6H4, OPh, NHSO2CF3, B(OH)2; R5 = OH, NH2, SO2CF3, SO2C6H4CF3, COCF3, Cl-6-alkoxy, Ph, C6H4Me, C6H4CO2H; NR4R5 = (un)substituted 5-membered aromatic heterocycle, optionally fused with 5- to 7-membered aromatic heterocycle (optionally substituted with F, Cl, Br, CF3, OCF3, CO2H, SO2Me, CN, Cl-4-alkoxy, Cl-4-alkyl, (Cl-4-alkyl)C6H4, (Cl-6-alkyl)-(Cl-6-alkoxy), (Cl-6-alkoxy)-(Cl-6-alkoxy), (Cl-6-alkoxy)-(Cl-6-alkoxy)C6H4, OPh), in addition to their physiol. compatible salts and to a method for their production.

The compds. are suitable for treating and/or preventing disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part.


IT 753459-78-8P
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and saponification of; preparation of 1,3-disubstituted cycloalkane

heterocyclic derivs. for use in treating metabolic disorders)

RN 753459-78-8 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 753459-40-4P 753459-41-5P 753459-42-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-disubstituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)

RN 753459-40-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-41-5 CAPLUS

CN Benzoic acid, 2-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-42-6 CAPLUS

CN Benzoic acid, 2-fluoro-6-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-44-8 CAPLUS

CN Benzoic acid, 4-methoxy-2-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-45-9 CAPLUS

CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy-4-(2-methylpropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-46-0 CAPLUS

CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxyethoxy-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2004:740108 CAPLUS

DOCUMENT NUMBER: 141:260734

TITLE: Preparation of diarylcycloalkyl oxazole derivatives and their use in the treatment of, e.g., fatty acid metabolism

INVENTOR(S): Goerlitzer, Jochen; Glombik, Heiner; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIKKD2



DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075815	A2	20040910	WO 2004-EP1584	20040227
WO 2004075815	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NA, NI, RW: BG, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GO, GR, ML, MR, NE, SN, TD, TG				
DE 10308353	A1	20041202	DE 2003-10308353	20030227
CA 2516573	AA	20040910	CA 2004-2516573	20040219
EP 1599454	A2	20051130	EP 2004-712502	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004204462	A1	20041014	US 2004-789019	20040227
NO 2005004381	A	20050921	NO 2005-4381	20050921
NO 2005004382	A	20050921	NO 2005-4382	20050921
PRIORITY APPLN. INFO.:			DE 2003-10308353	A 20030227
			DE 2003-10308351	A 20030227
			US 2003-494911P	P 20030813
			WO 2004-EP1584	W 20040219

OTHER SOURCE(S): MARPAT 141:260734
GI


AB Title compds. I [A = cycloalkanediyl, cycloalkenediyl, etc.; B = Ph, heterocyclic, etc.; R1 = SCF3, OCF2-CHF2, phenoxy, etc.; R2 = H, CF3; R3 = H, alkyl; R4 = Ph, H, F, Cl, Br, etc.; R5 = H, F, Cl, Br, OH, etc.; X, Y = alkanediyl, etc.] are prepared. For instance,

2-Methyl-6-[(1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy]benzoic acid (II) is prepared in 7 steps using naphthalene-2-carboxaldehyde, diacetylmonooxime, 1,3-cyclohexanediol and 2-bromomethyl-6-methylbenzoic acid Me ester. II has an EC50 = 0.2 nM for the PPAR α receptor. I are useful for treating disorders of the fatty acid metabolism and glucose utilization in addition to disorders of insulin resistance.

IT 755016-26-3P, 2-[(1R,3S)-3-((2-(3-fluoro-5-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy]methylbenzoic acid methyl ester (III) (PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)

RN 755016-26-3 CAPLUS
CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-fluoro-5-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 755016-12-7P, 2-Methyl-6-[(1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy]methylbenzoic acid
755016-20-5P, 2-[(1R,3S)-3-((5-Methyl-2-(4-


((trifluoromethyl)phenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy]methyl-6-methylbenzoic acid
755016-20-3P, 2-[(1R,3S)-3-((5-Methyl-2-(4-phenoxyphenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy]methyl-6-methylbenzoic acid
755016-27-4P, 2-[(1R,3S)-3-((2-(3-(2-Methoxyethoxy)-6-methylbenzoic acid

trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy]methyl-6-methylbenzoic acid
755016-28-5P, 2-Methyl-6-[(1R,3S)-3-((5-phenyl-2-(4-tolyl)oxazol-4-yl)methoxy)cyclohexyl)oxy]methylbenzoic acid
755016-30-5P, 2-[(1R,3S)-3-((2-(3-Methoxyphenyl)-5-phenoxyoxazol-4-yl)methoxy)cyclohexyl)oxy]methyl-6-methylbenzoic acid
755016-32-1P, 2-[(1R,3S)-3-((2-Cyclohexyloxazol-4-yl)methoxy)cyclohexyl)oxy]methyl-6-methylbenzoic acid
RN: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)

RN 755016-12-7 CAPLUS


CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(2-naphthalenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-20-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(trifluoromethyl)thio)phenyl]-4-oxazolyl)methoxy)cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-23-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-24-1 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1R,3S)-3-[(5-methyl-2-(4-phenoxyphenyl)-4-oxazolyl)methoxy)cyclohexyl]oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-27-4 CAPLUS
CN Benzoic acid, 2-[(1R,3S)-3-((2-(3-(2-methoxyethoxy)-5-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-28-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-(4-methylphenyl)-5-phenyl-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-30-9 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-32-1 CAPLUS
CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-cyclohexyl-4-oxazolyl)methoxy)cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 755016-11-6P, 2-Methyl-6-(((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methylbenzoic acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent);
(preparation of diarylcycloalkyl oxazole derivs. and their use in treatment

of, e.g., fatty acid metabolism)

RN 755016-11-6 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazolyl)methoxy)cyclohexyl]oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L8 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:701970 CAPLUS
DOCUMENT NUMBER: 141:225511
TITLE: Preparation of substituted azoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions
INVENTOR(S): Mjallli, Adnan M. M.; Andrews, Robert C.; Yerragunta, Ravindra R.; Xie, Rongyuan; Ren, Tan; Subramanian, Govindan; Quada, James C., Jr.
PATENT ASSIGNEE(S): Transtech Pharma Inc., USA
SOURCE: PCT Int. Appl., 224 pp.
CODEN: PIXPD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071448	A2	20040826	WO 2004-US4076	20040212
WO 2004071448	A3	20041014		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, S2, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004186151	A1	20040923	US 2004-777471	20040212
PRIORITY APPLN. INFO.:			US 2003-446924P	P 20030212

OTHER SOURCE(S): MARPAT 141:225511
GI




AB Title imidazoles and analogs I (wherein m, n = independently 0, 1; A = H, alkyl, alkenyl, alkynyl; L1 = a bond, O, alkylene, CO, NHCO, NH, NHSO2, etc.; R1 = O, S; NR4 = X = a bond, CO, CH2, SO2; R2 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, perfluoroalkyl, alkyne optionally interrupted by one or more heteroatoms, (hetero)aryl, heterocyclyl, etc.; R3 = H, alkyl, (cyclo)alkylalkylene, (hetero)aryl(alkylene); R4 = H, alkyl, (hetero)aryl(alkyl), heterocyclyl(alkyl), etc.; Ar1 = (un)substituted optionally fused (hetero)arylene; and pharmaceutically acceptable salts, solvates, and prodrugs thereof) were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, 3-((tert-butoxy-3-butoxycarbonylphenyl)amino)-2-(4-nitrophenyl)imidazole was coupled with 4-nitrophenacyl bromide to give the keto ester, which was treated with ammonium acetate in glacial acetic acid/anhydrous DMF to afford the imidazole

II (40%). Compds. of the invention inhibited PTP 1B activity with IC50 values ranging from about 0.01 μ M to about 20 μ M. Thus, I and pharmaceutical compns. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone

or cytokines, of Alzheimer's disease (no data).
IT 745833-78-7P 745833-81-2P, 4-[(4-[(2S)-2-[(4-(2,4-Dichlorophenyl)oxazol-2-yl)-2-[(2-(4-methoxyphenyl)acetyl)amino]ethyl]-2-nitrophenoxy)methyl]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)


L8 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 745833-78-7 CAPLUS
 CN Benzoic acid,
 4-[(2-amino-4-[(2S)-2-[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[(cis-6-ethylcyclohexyl)carbonyl]amino]ethyl)phenoxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 745833-81-2 CAPLUS
 CN Benzoic acid, 4-[(4-[(2S)-2-[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[(4-methoxyphenyl)acetyl]amino]ethyl)-2-nitrophenoxy]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title oxazoles I [Z = cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, etc.; R3 = H, Me; X, Y = alkyl (chains may contain 1 or more oxygens)] are prepared.

Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(Iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and


syndrome X. The bioactivity of II was determined (EC50 = 0.3 nM vs. PPAR α).

IT 710281-34-OP, 2-[(1R,3S)-3-[(2-(3-Bromophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-44-0 CAPLUS

CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ACCESSION NUMBER: 2004:513338 CAPLUS
 DOCUMENT NUMBER: 141:71532
 TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendl; Keil, Stefanie; Schaefer, Hans-Ludwig; Schwink, Lothar; Wendl, Wolfgang
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 231,432.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
US 2005267177	A1	20051201	US 2005-97345	20050404
			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801


PRIORITY APPLN. INFO.: OTHER SOURCE(S): MARPAT 141:71532
 GI

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 710281-30-4P, Methyl 2-[(1R,3S)-3-[(2-(3-Fluorophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoate
 710281-32-6P, 2-[(1R,3S)-3-[(2-(3-Fluorophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-33-7P, 2-[(1R,3S)-3-[(2-(3-Methoxyphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-34-8P, 2-[(1R,3S)-3-[(2-(3-Fluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-35-9P, 2-[(1R,3S)-3-[(2-(3-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-36-0P, 2-[(1R,3S)-3-[(2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-37-1P, 2-[(1R,3S)-3-[(2-(3-Methylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-38-2P, 2-[(1R,3S)-3-[(2-(3-Dimethylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-39-3P, 2-[(1R,3S)-3-[(2-(2,4-Dimethylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-40-4P, 2-[(1R,3S)-3-[(2-(2-Methylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-41-7P, 2-[(1R,3S)-3-[(2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-42-8P, 2-[(1R,3S)-3-[(2-(3,4-Dimethylphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-43-9P, 2-[(1R,3S)-3-[(2-(3-Cyanophenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-45-1P, 2-Methyl-6-[(1R,3S)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy)methylbenzoic Acid 710281-46-2P,
 2-Methyl-6-[(1S,3R)-3-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclohexyl]oxy)methylbenzoic Acid 710281-48-4P,
 2-Methyl-6-[(1R,3S)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy)methylbenzoic Acid 710281-49-5P,
 2-Methyl-6-[(1S,3R)-3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]cyclohexyl]oxy)methylbenzoic Acid 710281-50-8P,
 2-[(1R,3S)-3-[(2-(4-Methoxyphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-51-9P, 2-[(1S,3R)-3-[(2-(4-Methoxyphenyl)-5-methyloxazol-4-yl)methoxy]cyclohexyl]oxy)methyl-6-methylbenzoic Acid
 710281-56-4P, 2-Methyl-6-[(1S,4R)-4-[(5-methyl-2-phenyloxazol-4-yl)methoxy]cyclopent-2-enyl]oxy)methylbenzoic Acid,
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)


RN 710281-30-4 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-32-6 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 710281-33-7 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-34-8 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(3-trifluoromethylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-39-3 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-40-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-41-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(3-trifluoromethoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 710281-35-9 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-36-0 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-37-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-38-2 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-42-8 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-43-9 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(3-cyanophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-45-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-46-2 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-48-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,3S)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-49-5 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



IT 501362-02-3P 501362-03-4P 501362-06-7P
501362-08-0P 501362-12-5P 501362-15-8P
501362-16-9P 501362-21-6P 501362-25-0P
501362-26-1P 501362-27-2P 501362-28-3P
501362-29-4P 501362-30-7P 501362-31-8P
501362-32-9P 501362-33-0P 501362-34-1P
501362-35-2P 501362-36-3P 501362-37-4P
501362-38-5P 501362-39-6P 501362-43-2P
501362-45-4P 501362-46-5P 501362-47-6P
501362-48-7P 501362-49-8P 501362-50-1P
501362-52-3P 501362-53-4P 501362-54-5P
501362-55-6P 501362-58-9P 501362-59-0P
501362-60-3P 501362-61-4P 501362-62-5P
501362-65-8P 501362-67-0P 501362-70-5P
501362-73-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOC (Biological study); PREP (Preparation); USES (Uses)
(preparation and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-02-3 CAPLUS
CN Benzoic acid, 2-[(13-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-03-4 CAPLUS
CN Benzoic acid, 2-[(1S,3R)-3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 710281-50-8 CAPLUS
CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-51-9 CAPLUS
CN Benzoic acid, 2-[(1S,3R)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-56-4 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 710281-55-3P, Methyl 2-methyl-6-[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclopent-2-enyl]oxy)methylbenzoate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-55-3 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy)methyl-, methyl ester (9CI)
(CA




RN 501362-06-7 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-09-0 CAPLUS
CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-12-5 CAPLUS
CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-15-8 CAPLUS


L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 5-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-16-9 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-21-6 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-25-0 CAPLUS
 CN Benzoic acid, 2-[[{[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl}-3-cyclohexen-1-yl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-26-1 CAPLUS
 CN Benzoic acid, 2-[[{[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl}cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-27-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[{[(1R,2R)-2-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl}-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 501362-28-3 CAPLUS
 CN Benzoic acid, 2-[(4-fluorophenyl)-4-oxazolyl]methoxy)cyclohexyl]ox y)methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-29-4 CAPLUS
 CN Benzoic acid, 2-[[{[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]-2-cyclopenten-1-yl}oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-30-7 CAPLUS
 CN Benzoic acid, 2-[[{[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclooctyl}oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-31-8 CAPLUS
 CN Benzoic acid, 2-[[{[(1R,2R)-2-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclooctyl]oxy]methyl}-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-32-9 CAPLUS
 CN Benzoic acid, 2-[[{[(1R,2S)-2-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl}cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-33-0 CAPLUS
 CN Benzoic acid, 2-[[{[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl}cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-34-1 CAPLUS
 CN Benzoic acid, 2-[[{[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl}cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-35-2 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]methoxy]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-36-3 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]methoxy]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS
 CN Benzoic acid, 2-[(trans-4-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)methoxy]-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 2-[(3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-48-7 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-38-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-39-6 CAPLUS
 CN Benzoic acid, 2-[(2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl)-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-43-2 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-45-4 CAPLUS




RN 501362-50-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-4-oxazolylmethoxybenzoic acid (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-59-0 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-cyanophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-65-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(1R,3S)-3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-67-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-70-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(1R,3S)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-73-8 CAPLUS
 CN Benzoic acid, 2-[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-01-2P 501362-08-9P 501362-11-4P
 501362-14-7P 501362-19-2P 501362-20-5P
 501362-42-1P 501362-69-2P 501362-72-7P
 501362-75-0P 501362-77-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-01-2 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-08-9 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-4-oxazolylmethoxybenzoic acid methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-11-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS
 CN Benzoic acid, 2-[(3-[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-19-2 CAPLUS
 CN Benzoic acid, 5-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-2-methyl-, ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-20-5 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-42-1 CAPLUS
 CN Benzoic acid, 2-[[3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-69-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-72-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-75-0 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-77-2 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-44-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
 RN 501362-44-3 CAPLUS
 CN Benzoic acid, 2-[[3-[(2-(3-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




IT 501362-64-7P 501362-78-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
 RN 501362-64-7 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-4-

Absolute stereochemistry. Rotation (-).



RN 501362-78-3 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:
 THIS

65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 2004:453192 CAPLUS

DOCUMENT NUMBER: 141:6919

TITLE: Preparation of substituted aralkyl derivatives as antidiabetic, hypolipidemic and hypocholesterolemic agents

INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Jain, Mukul R.; Basu, Sujay; Pingali, Harikishore; Raval, Saurin K.; Raval, Preeti S.

PATENT ASSIGNEE(S): Cadila Healthcare Limited, India

SOURCE: PCT Int. Appl., 114 pp.


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046119	A1	20040603	WO 2003-IN358	20031114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2506112	AA	20040603	CA 2003-2506112	20031114
EP 1569916	A1	20050907	EP 2003-808341	20031114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015713	A	20050913	BR 2003-15713	20031114
NO 200502413	A	20050726	NO 2005-2413	20050513
PRIORITY APPLN. INFO.:			IN 2002-MU992	A 20021115
			IN 2003-MU792	A 20030812
			WO 2003-IN358	W 20031114

OTHER SOURCE(S): MARPAT 141:6919
GI

I


AB The present invention relates to novel substituted aralkyl derivs. of formula A(CH₂)_nX-Ar-CH₂CH(R)CHR1R2 [A = (substituted) aryl, heteroaryl,

L8 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
heterocycl: n = 1-3; X = O, S; Ar = arom., heteroarom. or heterocyclic group; R, R1 = (substituted) amino, (substituted) OH, N3, CN, COOH, tetrazolyl, etc.; R2 = H, alkyl, cycloalkyl, their derivs., their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compns. contg. them, use of these compds. in medicine and the intermediates involved in their prepn. The compds. are useful as antidiabetic, hypolipidemic and hypocholesterolemic agents. Thus, I was prep'd., and lowered serum triglyceride in Swiss albino mice by 78%.

IT 696662-51-8 696662-69-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aralkyl derivs. as antidiabetic, hypolipidemic and hypocholesterolemic agents)


RN 696662-51-8 CAPLUS
CN Benzoic acid, 2-[(2S)-2-ethoxy-3-{4-[(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl}propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 696662-69-8 CAPLUS
CN Benzoic acid, 2-[(2S)-2-ethoxy-3-{4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl}propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 696663-42-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aralkyl derivs. as antidiabetic, hypolipidemic and hypocholesterolemic agents)

RN 696663-42-0 CAPLUS
CN Benzoic acid, 2-[(2S)-2-ethoxy-3-{4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]propoxy}-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

ACCESSION NUMBER: 2003:202470 CAPLUS

DOCUMENT NUMBER: 138:238169

TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators

INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schaefer, Hans-Ludwing; Schwink, Lothar; Wendler, Wolfgang

PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany

SOURCE: PCT Int. Appl., 83 pp.

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PG, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
CA 2458210	AA	20030313	CA 2002-2458210	20020817
EE 200400059	A	20040415	EE 2004-59	20020817
EP 1425014	A1	20040609	EP 2002-797589	20020817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012158	A	20040713	BR 2002-12158	20020817
CN 1549713	A	20041124	CN 2002-817085	20020817
JP 2005525294	T2	20050825	JP 2003-524576	20020817
NZ 531440	A	20051028	NZ 2002-531440	20020817
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
NO 2004000811	A	20040519	NO 2004-811	20040224
BG 108598	A	20050331	BG 2004-108598	20040224

PRIORITY APPLN. INFO.: DE 2001-10142734 A 20010831
DE 2002-10223273 A 20020524
WO 2002-EP9221 W 20020817

OTHER SOURCE(S): MARPAT 138:238169
GI




AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I (Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, Cl-6-alkyl O-(Cl-6-alkyl); R3 = H, Cl-6-alkyl; X, Y = Cl-6-alkyl (chains may contain 1 or more oxygens) to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPARα].

IT 501362-02-3P 501362-03-4P 501362-06-7P
 501362-09-0P 501362-12-5P 501362-15-8P
 501362-16-9P 501362-21-6P 501362-25-0P
 501362-26-1P 501362-27-2P 501362-29-3P
 501362-29-4P 501362-30-7P 501362-31-8P
 501362-32-9P 501362-33-0P 501362-34-1P
 501362-35-2P 501362-36-3P 501362-37-4P
 501362-38-5P 501362-39-6P 501362-43-2P
 501362-45-4P 501362-46-5P 501362-47-6P
 501362-48-7P 501362-49-8P 501362-50-1P
 501362-52-3P 501362-53-4P 501362-54-5P
 501362-58-6P 501362-59-9P 501362-59-0P
 501362-60-3P 501362-61-4P 501362-62-5P
 501362-65-8P 501362-67-0P 501362-70-5P
 501362-73-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PREP (Preparation); USES (Uses)
 (preparation and PPAR activating activity; preparation of oxazole diaryl

cycloalkyl derivs. and the use thereof as PPAR activators)
 RN 501362-02-3 CAPLUS
 CN Benzoic acid, 2-[(13-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-03-4 CAPLUS
 CN Benzoic acid, 2-[(1S,3R)-3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-06-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-09-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-12-5 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-15-8 CAPLUS
 CN Benzoic acid, 5-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-16-9 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-21-6 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-25-0 CAPLUS
 CN Benzoic acid, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl)-3-cyclohexen-1-yl]methoxy)methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-26-1 CAPLUS
 CN Benzoic acid, 2-[(1-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]methyl)cyclohexyl]methoxy)methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-27-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-{{(1R,2R)-2-((2-phenyl-4-oxazolyl)methoxy)cyclohexyl)oxy}methyl}-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-28-3 CAPLUS
 CN Benzoic acid, 2-{{(4-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy}methyl}-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-29-4 CAPLUS
 CN Benzoic acid, 2-{{(4-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)-2-cyclopenten-1-yl)oxy}methyl}-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-30-7 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-4-fluorophenyl)-4-oxazolyl)methoxy)cyclooctyl)oxy}methyl}-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-31-8 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-4-fluorophenyl)-4-oxazolyl)methoxy)cyclooctyl)oxy}methyl}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-32-9 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)methoxy}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-33-0 CAPLUS
 CN Benzoic acid, 2-{{(3-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)methyl)cyclohexyl)methoxy}-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-34-1 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)methyl)cyclohexyl)oxy}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-35-2 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)methoxy}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-36-3 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)methoxy}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)methoxy}-6-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-38-5 CAPLUS
 CN Benzoic acid, 2-{{(2-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)ethyl}-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-39-6 CAPLUS
 CN Benzoic acid, 2-[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]ethyl-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-43-2 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-45-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(2-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-48-7 CAPLUS
 CN Benzoic acid, 2-[(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(3-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-59-0 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-cyanophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-phenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl)oxy]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-65-8 CAPLUS
 CN Benzoic acid, 2-[[((1R,3S)-3-((2-(4-methoxyphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-67-0 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1R,3S)-3-((2-phenyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-70-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1R,3S)-3-((2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-73-8 CAPLUS
 CN Benzoic acid, 2-[[((1S,3R)-3-((2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS
 CN Benzoic acid, 2-[[((1R,3S)-3-((2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-19-2 CAPLUS
 CN Benzoic acid, 5-[[((1R,3S)-3-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-2-methyl-, ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-20-5 CAPLUS
 CN Benzoic acid, 2-[[((1R,3S)-3-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-5-methyl-, ethyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 501362-01-29 501362-08-99 501362-11-4P
 501362-14-7P 501362-19-2P 501362-20-5P
 501362-42-1P 501362-69-2P 501362-72-7P
 501362-75-0P 501362-77-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and
 the use thereof as PPAR activators)
 RN 501362-01-2 CAPLUS
 CN Benzoic acid,
 2-((3-((2-(4-fluorophenyl)-4-oxazolyl)methoxy)cyclohexyl)ox y)methyl)-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-08-9 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1S,3R)-3-((2-phenyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-11-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1S,3R)-3-((2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-42-1 CAPLUS
 CN Benzoic acid, 2-((3-((2-(4-bromophenyl)-5-methyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl)-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-69-2 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1R,3S)-3-((2-phenyl-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-72-7 CAPLUS
 CN Benzoic acid, 2-methyl-6-[[((1R,3S)-3-((2-(4-methylphenyl)-4-oxazolyl)methoxy)cyclohexyl)oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-75-0 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-77-2 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 501362-44-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)
 RN 501362-44-3 CAPLUS
 CN Benzoic acid, 2-[[3-[(2-(3-bromophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



IT 501362-64-7P 501362-78-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

L8 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:772613 CAPLUS
 DOCUMENT NUMBER: 133:335164
 TITLE: Tri-aryl acid derivatives as PPAR receptor ligands
 INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael P.; Labaudiniere, Richard F.; Zhang, Litoa; Caulfield, Thomas J.; Minnich, Anne; Bobko, Mark; Morris, Robert; Gronberg, Robert D.; McGarry, Daniel G.
 PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
 SOURCE: PCT Int. Appl., 257 pp.
 CODEN: PIIXD2.

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064876	A1	20001102	WO 2000-US11490	20000428
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, MZ, LC, LK, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SI, TM, TR, TT, TZ, UA, UD, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GM, ML, MR, NE, SN, TD, TG				
CA 2371303	AA	20001102	CA 2000-2371308	20000428
EP 1177176	A1	20020206	EP 2000-930210	20000428
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010126	A	20020226	BR 2000-10126	20000428
EE 200100558	A	20021216	EE 2001-558	20000428
NZ 515007	A	20031128	NZ 2000-515087	20000428
AU 782404	B2	20050728	AU 2000-48070	20000428
ZA 2001008800	A	20030310	ZA 2001-8800	20011024
NO 2001005226	A	20011202	NO 2001-5226	20011025
HR 2001000793	A1	20020228	HR 2001-793	20011026
HK 1047098	A1	20050520	HK 2002-108625	20021129
PRIORITY APPLN. INFO.:				
			US 1999-131454P	P 19990428
			WO 2000-US11490	W 20000428

OTHER SOURCE(S): MARPAT 133:335164
 GI

L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Preparation; THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn., methanolysis and PPAR activating activity of; prepn. of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)


RN 501362-64-7 CAPLUS
 CN Benzoic acid, 2-[[[(1S,3R)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





RN 501362-78-3 CAPLUS
 CN Benzoic acid, 2-[[[(1R,3S)-3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L8 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB This invention is directed to triaryl acid derivs. I and their salts, O-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcy cloalkenyl, fused heteroarylcy cloalkyl, fused heteroarylheterocyclyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tplbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonylaminocarbonyl, sulfonylaminocarbonyl, carbamoyl, tetrazolyl, etc.; R1, R2, R3, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-4; p = 0-4; q = 0-6; with numerous provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid undergoes a sequence of: (1) Me esterification, (2) benzylic monobromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alkaline hydrolysis with NaOH in aqueous EtOH, to give title compound II.

IT 303218-33-9P 303219-47-5P 303219-55-8P

303219-57-0P 303219-59-2P 303220-12-4P

303220-98-6P 303221-36-5P 303221-38-7P


303221-40-1P 303221-44-5P 303221-87-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological


study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tri-aryl acid derivs. as PPAR receptor ligands)

RN 303218-33-9 CAPLUS


CN Benzoic acid, 2-methyl-6-[[3-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 303218-47-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy)methyl]- (9CI) (CA INDEX NAME)




RN 303219-55-8 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 303219-57-0 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 303219-59-2 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)





RN 303221-40-1 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 303221-44-5 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 303221-87-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 303220-12-4 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy)methyl]- (9CI) (CA INDEX NAME)



RN 303220-98-6 CAPLUS
 CN Benzoic acid, 2-methyl-6-[(3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-36-5 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-cyclohexyl-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-38-7 CAPLUS
 CN Benzoic acid, 2-[(3-[(2-(3-fluorophenyl)-4-oxazolyl)methoxy]phenoxy)methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1994:54537 CAPLUS

DOCUMENT NUMBER: 120:54537

TITLE: Preparation of 4-(phenoxyalkyl)-2-oxazolines as

acaricides and insecticides

INVENTOR(S): Hirose, Taro; Kisida, Hiroshi; Saito, Shigeru;

Fujiwara, Hiroaki

PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 53 pp.

CODEN: EPDKDW


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 553623	A1	19930804	EP 1993-100223	19930108
EP 553623	B1	20010404		
R: CH, DE, ES, FR, GB, IT, LI				
AU 9230491	A1	19930729	AU 1992-30491	19921231
AU 658955	B2	19950504		
ES 2155442	T3	20010516	ES 1993-100223	19930108
BR 9302099	A	19930803	BR 1993-299	19930127
JP 05271206	A2	19931019	JP 1993-11698	19930127
JP 3239508	B2	20011217		
US 5411979	A	19950502	US 1993-10015	19930127
PRIORITY APPN. INFO.:			JP 1992-12967	A 19920128

OTHER SOURCE(S): MARPAT 120:54537
GI

AB Title compds. (I: H, halo, (halo)alkyl, alkoxy, etc.; R2 = H, halo, alkyl, alkoxy, alkylthio; R3 = H, Me; R4 = (substituted) Ph; p = 1-4) were prepared. Thus, 4-(Me3C)C6H4OH was condensed with BrCH2CH(OMe)2 and the product converted in 4 steps to 4-(Me3C)C6H4OCH2CH(NH2)CH2OH which was cyclocondensed with 2,6-F2C6H2COCl to give I (R1 = CMe3, R2 = R3 = H, R4 = C6H3F2-2,6) which gave ≥90% control of Culex pipiens pallens larvae in H2O containing 3.5 ppm.

IT 151856-99-4P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as acaricide and insecticide)

RN 151856-99-4 CAPLUS
CN Benzoic acid, 3-chloro-4-[4-[(2-(2,6-difluorophenyl)-4,5-dihydro-4-oxazolyl)methoxy]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1973:45070 CAPLUS

DOCUMENT NUMBER: 78:45070

TITLE: Oxazole derivatives as fluorescent whiteners

INVENTOR(S): Matsuo, Masatoshi; Sakaguchi, Tadao; Akamatsu, Takashi

PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.

SOURCE: Fr., 67 pp.

CODEN: FRXXAK

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2066252		19710910		
DE 2050371				DE
GB 1323550				GB
JP 47010286		19720000	JP	
JP 47011924		19720000	JP	
JP 47022284		19720000	JP	
JP 48002305		19730000	JP	
JP 48002306		19730000	JP	
JP 48002307		19730000	JP	
JP 48002308		19730000	JP	
JP 48002309		19730000	JP	
JP 48002310		19730000	JP	
JP 48002311		19730000	JP	
JP 48002312		19730000	JP	
JP 48032304		19730000	JP	
JP 48032305		19730000	JP	
JP 48032306		19730000	JP	
JP 48032307		19730000	JP	
JP 48032308		19730000	JP	
JP 48032309		19730000	JP	
JP 48032310		19730000	JP	
JP 48032311		19730000	JP	
JP 48032312		19730000	JP	
JP 48032411		19730000	JP	
JP 48032566		19730000	JP	
JP 48037124		19730000	JP	
JP 48041116		19730000	JP	
JP 48041794		19730000	JP	
JP 49000432		19740000	JP	
JP 49000976		19740000	JP	
JP 49013952		19740000	JP	
JP 49014325		19740000	JP	
US 3843632		19740000	US	
PRIORITY APPN. INFO.:		JP 1969-03990		19691021

AB Approx. 270 oxazole fluorescent whiteners of general structures I and II were prepared, where O = p-C6H4CH:CH, p-C6H4CH:CHC6H4-p, p-C6H4, CH:CH, C10H8, or a 5- or 6-membered heterocyclic group; R1, R2, R3, and R4 = lower alkyl, cyclohexyl, Ph or substituted Ph, or (SR4) = benzo or naphtho, R5 = 0 or 1, and R6 = CN, Cl, CO2H, CO2Et, MeO or carbamoyl. Thus, 4-C10OC6H4CH:CHC6H4COCl-4 was condensed with MeOC6H4PhH2 and the product heated in H2SO4 to give fluorescent whitener III (31768-38-4).

In another example, β-(benzoxazole-2-yl)acryloyl chloride was condensed with 4-C10OC6H4COCH2NH2 followed by heating in polyphosphoric acid to give


DOCUMENT NUMBER: 120:54537 CAPLUS




L8 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
fluorescent whitener IV (38215-18-8). Similarly prep'd. Was fluorescent whitener II (R1 = R2 = Me, n = 0, R5 = 4-COONH2) (31768-39-5).

IT 40875-07-0P 40875-08-9P
RL: IMP (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 40875-07-8 CAPLUS
CN Benzoic acid, 3-[2-(2-(5-phenyl-2-oxazolyl)ethenyl)phenyl]ethenyl- (9CI) (CA INDEX NAME)



RN 40875-08-9 CAPLUS
CN Benzoic acid, 3-[2-(2-(5-phenyl-2-oxazolyl)ethenyl)phenyl]ethenyl- ethyl ester (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	98.47	437.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.25	-14.25

STN INTERNATIONAL LOGOFF AT 08:07:26 ON 07 FEB 2006